Compare Baxter International Inc (BAX) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs JD.Com Inc — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while JD.Com Inc trades at $29.39 (market cap $39.64B). The key difference: JD.Com Inc is far larger — about 3.5× Baxter International Inc's market cap, and JD.Com Inc pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| BAX | JD | |
|---|---|---|
Market Cap | $11.26B | $39.64B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.22 | $36.17 |
52-Week Low | $15.80 | $25.19 |
Enterprise Value | $18.93B | $25.80B |
Dividend Yield | 0.92% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
JD.com trades at $28.88, up 2.41% today, with strong technical momentum and bullish analyst sentiment. Recent earnings beats and a consensus price target of $40 suggest significant upside potential. The company maintains robust revenue growth, reaching $1.31 trillion in 2025, though net margins compressed to 1.05%. Positive news highlights retail margin expansion and AI-driven investments.
Outlook remains favorable with Wall Street's 70% buy rating, but risks include Chinese regulatory scrutiny and ongoing margin pressures. The stock's current valuation at P/E 21.2 appears reasonable given growth prospects, though investors should monitor earnings sustainability and geopolitical factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
